PT - JOURNAL ARTICLE AU - Onkar S. Bains AU - Thomas A. Grigliatti AU - Ronald E. Reid AU - K. Wayne Riggs TI - Naturally Occurring Variants of Human Aldo-Keto Reductases with Reduced In Vitro Metabolism of Daunorubicin and Doxorubicin AID - 10.1124/jpet.110.173179 DP - 2010 Dec 01 TA - Journal of Pharmacology and Experimental Therapeutics PG - 533--545 VI - 335 IP - 3 4099 - http://jpet.aspetjournals.org/content/335/3/533.short 4100 - http://jpet.aspetjournals.org/content/335/3/533.full SO - J Pharmacol Exp Ther2010 Dec 01; 335 AB - Doxorubicin (DOX) and daunorubicin (DAUN) are effective anticancer drugs; however, considerable interpatient variability exists in their pharmacokinetics. This may be caused by altered metabolism by nonsynonymous single-nucleotide polymorphisms (ns-SNPs) in genes encoding aldo-keto reductases (AKRs) and carbonyl reductases. This study examined the effect of 27 ns-SNPs, in eight human genes, on the in vitro metabolism of both drugs to their major metabolites, doxorubicinol and daunorubicinol. Kinetic assays measured metabolite levels by high-performance liquid chromatography separation with fluorescence detection using purified, histidine-tagged, human wild-type, and variant enzymes. Maximal rate of activity (Vmax), substrate affinity (Km), turnover rate (kcat), and catalytic efficiency (kcat/Km) were determined. With DAUN as substrate, variants for three genes exhibited significant differences in these parameters compared with their wild-type counterparts: the A106T, R170C, and P180S variants significantly reduced metabolism compared with the AKR1C3 wild-type (Vmax, 23–47% decrease; kcat, 22–47%; kcat/Km, 38–44%); the L311V variant of AKR1C4 significantly decreased Vmax (47% lower) and kcat and kcat/Km (both 43% lower); and the A142T variant of AKR7A2 significantly affected all kinetic parameters (Vmax and kcat, 61% decrease; Km, 156% increase; kcat/Km, 85% decrease). With DOX, the R170C and P180S variants of AKR1C3 showed significantly reduced Vmax (41–44% decrease), kcat (39–45%), and kcat/Km (52–69%), whereas the A142T variant significantly altered all kinetic parameters for AKR7A2 (Vmax, 41% decrease; kcat, 44% decrease; Km, 47% increase; kcat/Km, 60% decrease). These findings suggest that ns-SNPs in human AKR1C3, AKR1C4, and AKR7A2 significantly decrease the in vitro metabolism of DOX and DAUN.